# ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

> **NCT02991274** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 897 (actual)

## Conditions studied

- Locally Advanced or Metastatic EGFR(+) NSCLC Patients

## Interventions

- **PROCEDURE:** genomic testing of T790M mutation

## Key facts

- **NCT ID:** NCT02991274
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-16
- **Primary completion:** 2018-06-29
- **Final completion:** 2018-06-29
- **Target enrollment:** 897 (ACTUAL)
- **Last updated:** 2019-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991274, "ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02991274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*